Bausch Health Announces Vyzulta is Now Approved in South Korea
Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval from the Ministry of Food and Drug Safety in South Korea.
Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.1
“Vyzulta is an important treatment option for people suffering from glaucoma, and we are committed to securing additional regulatory approvals for Vyzulta in countries around the world,” Thomas J. Appio, president, Bausch + Lomb/International, said in a company news release. “Bausch + Lomb remains focused on bringing forward innovative eye health treatment options to help address unmet medical needs around the world.”
Vyzulta is now approved in nine markets, including Argentina, Canada, Colombia, Hong Kong, Mexico, South Korea, Taiwan, Ukraine and the United States.